A Mid-sized Sponsor Increased Site Count by 50% in a Rare Disease Clinical Trial with Medidata AI Intelligent Trials

A mid-sized biopharma company struggled to recruit patients and select strong sites for a rare-disease trial, in an environment where over a quarter of rare-disease trials from 2016-2020 were terminated for low patient accrual. The sponsor used Medidata AI Intelligent Trials to guide site selection, drawing on site recommendations tied to its own priority metrics, data-quality metrics, and historical performance benchmarked against industry standards. As a result, the sponsor achieved a 50% increase in site count for the trial. The page is a gated lead-generation landing page, so no further operational detail beyond this figure is shown.

The customer is anonymised in Medidata’s own case study — not withheld by us.

Medidata is a Dassault Systèmes company supplying the clinical-trial EDC and data platform (Rave) most sponsors and CROs already run live trials on, now with an AI layer built in.

This sits in the Ship stage of the AI use-case lifecycle: Named examples from the vendors pharma teams use to get an AI system live inside a real, regulated production workflow — validation, CRM, safety and clinical systems of record.